Plasmafabriek Sanquin


Wilfactin compensates for a deficiency of the Von Willebrand factor in patients with Von Willebrand disease.


Wilfactin compensates for a deficiency of the Von Willebrand factor

Wilfactin is administered when treatment using desmopressin is ineffective or impossible. Wilfactin is not suitable for the treatment of haemophilia A.

Product information

  • How is Wilfactin used?

    Wilfactin is injected intravenously into a blood vessel.

    The start and administration of treatment should be under the supervision of a physician experienced in the treatment of haemophilia. He/she will ensure the treatment processes is smoothly and, in the event of an allergic reaction, can take the required measures immediately.

    What dosage of Wilfactin is prescribed?

    • The physisian treating the patient specifies the dosage of Wilfactin. The dosage and the frequency depend on:
    • the patient’s weight;
    • the severity of the bleeding;
    • the patient’s health;
    • the results of blood tests;
    • the type of procedure.

    The dosage is expressed in the number of units (IU). The physician can adjust the dosage and frequency of injections on the basis of the results of blood tests.

    Adding coagulation factor VIII
    In conjunction with Wilfactin, it is sometimes necessary to use another factor VIII preparation (another coagulation protein). In this way a bleed can be prevented or treated more quickly in emergency situations or severe bleeding.

    Read more in the Wilfactin leaflet (pdf, in Dutch).

  • How is Wilfactin dissolved?

    • In general, the powder dissolves extremely quickly. After a maximum of ten minutes, it should be completely dissolved.
    • The solution should be clear or slightly milky.
    • Do not use any solution that is turbid or contains precipitations.
    • This medicine may not be mixed with any other medicines, with the exception of FACTANE (human coagulation factor VIII).
    • Do not dilute the dissolved product.
  • How is Wilfactin administered?

    • The product should be suctioned into a sterile syringe with the filter needle provided.
    • Remove the needle from the syringe and replace this by an intravenous or epicranial needle.
    • Remove any air in the syringe, disinfect the skin and insert the needle into the vein.
    • Administer the intravenous injection as one dose immediately after it has been prepared, and at a maximum rate of 4 ml/minute.

      Read more in the Wilfactin leaflet (pdf, in Dutch)
  • What are the side effects of Wilfactin?

    Wilfactin can cause side effects, in the same way as all other medicines. Not everyone suffers from these side effects. In rare cases, a patient’s body temperature may rise (hyperthermia).

    The development of inhibitors against the Von Willebrand factor is seldom observed in patients with the Von Willebrand disease.

    There is a risk of blood clots forming (thromboembolic episodes).

    For more information, please read the Wilfactin leaflet (pdf, in Dutch).

  • How is Wilfactin stored?

    • out of reach and sight of children
    • at a temperature between 0ºC and +25°C (therefore, do not freeze)
    • in the original packaging to protect it from the light

    Not to be used after the expiry date
    Do not use Wilfactin after its expiry date. This is stipulated on the label, (on the vial) and on the box.

    After being dissolved, the product should be used immediately. Do not use Wilfactin if the solution is turbid or contains precipitations.

    Patients can hand any used medicines over to a pharmacy. By not disposing of medicines via waste water or household waste, we are helping to protect the environment.

    Read more in the Wilfactin leaflet (pdf, in Dutch).